Low-Dose Naltrexone (LDN)
An immune-modifying agent used at 4.5 mg nightly in the NeoFertility protocol for patients with reduced egg reserve, suspected immune-mediated implantation failure, and clinical endorphin deficiency. Originally developed as an opioid antagonist at higher doses, LDN at low doses modulates immune function by temporarily blocking opioid receptors, triggering a compensatory increase in endorphin production. Published data from NeoFertility shows LDN use associated with significant enhancements in endometrial thickness, ovarian responsiveness, progesterone levels, and clinical pregnancy rates.
This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.